SiNtx Technologies Inc (SINT)

[boston745]

Looking a little deeper, revenue in 2021 for Zimmer/ZimVie spine division was 540m. 2022 that dropped to 450m, or 90m (16.8%) drop. 2023 looks to be around 390m or so showing a loss of about 60m. Thus ZimVie is selling its spine division for less than 1x 2023 revenue likely due to the fact that it keeps loosing revenue. Its one highlight seems to be Mobi-C, an asset acquired with LDR. This one glimmer maybe the main focus of the Hfund that is acquiring Zimvie's spinal assets.
One thing i found particularly interesting is that after Zimmer acquired LDR for 1 billion, Zimmer, for some reason, stopped trying to innovate its spine business. Now i could be wrong, but this suggests to me that it stopped in-house innovation because it had external innovations it was eyeing.

So I think, the underlying concern that we had with our portfolio was we haven't innovated since the acquisition of LDR, and we needed to continue to innovate the portfolio specifically to Mobi-C. So there's a couple of things we're doing there.

Direct quote from the CEO of ZimVie before it announced it was divesting its spine business. Maybe a coincidence, but Q4 (Oct) was when Sintx was able to compete directly with CTL and thus opens up the possibility that other companies could tap it for Spinal implant blanks. Of course things could be waiting for further development of 3D printed composites and/or metal coatings. Sintx has 3 different spinal material products it can compete via once composites and coatings receive clearance; Dense Ceramics, PEEK/Si3N4 blend, and Si3N4 coating titanium/metals. This is why i could see Zimmer Biomet stopping in-house innovation as well as selling off old assets as that could help it compete and grow in the $12 Billion Spinal market. That seems like a very large market to just tap out off like it did. I get why, if its product portfolio simply couldnt compete, it would need new ones if it wanted to again.

ZimmerBiomet and Sintx have some degree of working relationship as evidenced by their shared IP being used in development. So you know Zimmer Biomet is eyeing Sintx and has been for years.

ARTHROPLASTY (Silicon Nitride)
Renewed interest in silicon nitride’s use as
a femoral head and acetabular cup.

https://ir.sintx.com/news-events/press-releases/detail/95/amedica-announces-results-of-independent-femoral-head-wear
https://www.sciencedirect.com/science/article/abs/pii/S1751616119309099

Source of quotes:
https://www.fool.com/earnings/call-transcripts/2023/11/02/zimvie-zimv-q3-2023-earnings-call-transcript/
https://d1io3yog0oux5.cloudfront.net/_bc6ef537ba0848d2887aa50d320e05b6/sintx/db/443/4298/pdf/SINTX+Corporate+Overview+-+Jan+%2724+-+Rev+J.pdf

This is why Zimmer Biomet would be eyeing Sintx and its material!

Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.

https://www.mdpi.com/2571-6131/4/2/16/htm

========================================

Electromagnetic fields, metal implant corrosion, and dis-ease it causes


https://i.imgur.com/nLg7SXT.jpg

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172932779